Kongressthemen
The Head and Neck Cancer Drug Development Summit has been curated with the industry in mind. Development in the head and neck cancer space has entered the most active period to date, with emerging immunotherapy biotechs, leading biopharma companies, and pioneering academics racing to exploit this immunogenic tumor, validate early clinical data from broader solid tumor trials, and improve clinical outcomes in this indication with a high unmet medical need.
Kongressorganizer (PCO)
Hanson Wade
Anmerkungen
Brochure: https://go.evvnt.com/842127-0?pid=4832
Speakers: Lars Birgerson, Chief Executive Officer, Adlai Nortye, Sophia Randolph, Chief Medical Officer, Alexo Therapeutics Inc., Michael Needle, Chief Medical Officer, AVEO Oncology, and more.
https://go.evvnt.com/842127-2?pid=4832
Herr Customer Service
KategorienOnkologie
